Inna Geyler, DO
Family Medicine · Brooklyn, NYNPI 1184649592
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.0% of the total across 325 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AbbVie at 24.3% of the total. Reporting peaked in 2019 at $1,822 and has fallen 50.6% since, to $900 in 2025. Among family medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 325 payments — averaging $27.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$1K
- GSK$1K
- Novartis$1K
- Boehringer Ingelheim$586
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$406
- plus $3K from 28 others
What the payments were for
- Consulting fees$5306%
- Food & beverage$8,54794%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 92 | $2,211 |
| Amgen | 40 | $1,200 |
| GSK | 30 | $1,106 |
| Novartis | 40 | $1,001 |
| Boehringer Ingelheim | 4 | $586 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $406 |
| Amarin Pharma, Inc. | 19 | $371 |
| Lilly USA, LLC | 11 | $305 |
| AstraZeneca | 7 | $216 |
| Pfizer | 9 | $190 |
| E.r. Squibb & Sons, L.L.C. | 11 | $177 |
| Medtronic | 2 | $175 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Optinose US, Inc. | 1 | $122 |
| Sanofi-aventis U.S. LLC | 5 | $115 |
| Alkermes, Inc. | 4 | $107 |
| Ardelyx, Inc. | 3 | $93 |
| Shield Therapeutics Inc | 3 | $67 |
| Merck | 3 | $64 |
| Esperion Therapeutics, Inc. | 2 | $48 |
| Vifor Pharma, Inc. | 2 | $43 |
| Vistapharm, Inc. | 3 | $43 |
| Exact Sciences | 2 | $42 |
| Arbor Pharmaceuticals, Inc. | 2 | $40 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Johnson & Johnson | 1 | $29 |
| Gilead | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Novo Nordisk | 1 | $23 |
| Avanir Pharmaceuticals, Inc. | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,091 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanumetSitagliptin Phos/Metformin Hcl | 46 | $32,597 |
| ZenpepLipase/Protease/Amylase | 13 | $28,729 |
| LinzessLinaclotide | 31 | $25,486 |
| JardianceEmpagliflozin | 21 | $21,448 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $19,687 |
| TrulicityDulaglutide | 15 | $18,442 |
| Lactulose | 15 | $15,855 |
| CreonLipase/Protease/Amylase | 17 | $14,666 |
| TradjentaLinagliptin | 14 | $13,720 |
| Repatha SureclickEvolocumab | 22 | $11,370 |
| VascepaIcosapent Ethyl | 49 | $9,925 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $3,759 |
| Diclofenac Sodium | 34 | $2,604 |
| Icosapent Ethyl | 20 | $1,411 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 12 | $1,406 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $2,211 | $40,15248 claims |
| Boehringer IngelheimJardiance, Tradjenta | $586 | $35,16835 claims |
| MerckJanumet | $64 | $32,59746 claims |
| Aimmune Therapeutics, Inc.Zenpep | $125 | $28,72913 claims |
| GSKTrelegy Ellipta | $1,106 | $19,68732 claims |
| Lilly USA, LLCTrulicity | $305 | $18,44215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in Brooklyn
- Walford LindoBrooklyn$104K
- Fu Fu HeBrooklyn$101K
- Jonathan ChangBrooklyn$66K
- Rui TengBrooklyn$39K
- Wei WangBrooklyn$26K
- Raymond ChanBrooklyn$25K
- Mikhail KorogluyevBrooklyn$24K
- Louis BonavitaEast Syracuse$674K
- Martin MahoneyBuffalo$520K
- Scott BrehautClinton$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.